Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines

References

• Al-Jamal KT. (2013). Active drug targeting: lessons learned and new things to consider. Int J Pharm 454:525–6
   PubMed Web of Science ®Google Scholar
• Beck A, Reichert JM. (2014). Antibody-drug conjugates: present and future. MAbs 6:15–17
   PubMed Web of Science ®Google Scholar
• Beck A, Wurch T, Bailly C, Corvaia N. (2010). Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 10:345–52
   PubMed Web of Science ®Google Scholar
• Burris HA, Rugo HS, Vukelja SJ, et al. (2011). Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29:398–405
   PubMed Web of Science ®Google Scholar
• Cabanillas F, Bodey GP, Burgess MA, et al. (1979). Results of a phase II study of maytansine in patients with breast carcinoma and melanoma. Cancer Treat Rep 63:507–9
   PubMedGoogle Scholar
• Cassady JM, Chan KK, Floss HG, et al. (2004). Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull 52:1–26
   PubMed Web of Science ®Google Scholar
• Chen RW, Gopal AK, Smith SE, et al. (2011). Results from a pivitol phase II study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma (HL). J Clin Oncol 29:8031–9
   Google Scholar
• Crommelin DJ, Florence AT. (2013). Towards more effective advanced drug delivery systems. Int J Pharm 454:496–511
   PubMed Web of Science ®Google Scholar
• Demetzos C, Pippa N. (2014). Advanced drug delivery nanosystems (aDDnSs): a mini-review. Drug Deliv 21:250–7
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, et al. (2006). Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114–24
   PubMed Web of Science ®Google Scholar
• Erickson HK, Park PU, Widdison WC, et al. (2006). Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426–33
   PubMed Web of Science ®Google Scholar
• Girish S, Gupta M, Wang B, et al. (2012). Clinical pharmacology of trastuzumab emtasine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol 69:1229–40
   PubMed Web of Science ®Google Scholar
• Grainger DW. (2013). Connecting drug delivery reality to smart materials design. Int J Pharm 454:521–4
   PubMed Web of Science ®Google Scholar
• Haddish-Berhane N, Shah DK, Ma D, et al. (2013). On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: a PK/PD approach. J Pharmacokinet Pharmacodyn 40:557–71
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Dirix L, Kocsis J, et al. (2013). Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 31:1157–63
   PubMed Web of Science ®Google Scholar
• Junttila TT, Li G, Parsons K, et al. (2011). Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 128:347–56
   PubMed Web of Science ®Google Scholar
• Kirsh, R, Hood, S, Brook C, et al. (2013). Will nanomedicine deliver on its promise of changing therapeutics or remain an interesting and important research tool in cell biology and physiology? Int J Pharm 545:530–1
   Web of Science ®Google Scholar
• Krop IE, LoRusso P, Miller KD, et al. (2012). A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, ataxane, and capecitabine. J Clin Oncol 30:3234–41
   PubMed Web of Science ®Google Scholar
• Lammers T. (2013). Smart drug delivery systems: back to the future vs. clinical reality. Int J Pharm 545:527–9
   Web of Science ®Google Scholar
• Lewis PGD, Li G, Dugger DL, et al. (2008). Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68:9280–90
   PubMed Web of Science ®Google Scholar
• Lianos GD, Vlachos K, Zoras O, et al. (2014). Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. Onco Targets Ther 7:491–500
   PubMed Web of Science ®Google Scholar
• Mastrobattista E. (2013). Advanced drug delivery in motion. Int J Pharm 545:517–20
   Web of Science ®Google Scholar
• Oflazoglu E, Kissler KM, Sievers EL, et al. (2008). Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 142:69–73
   PubMed Web of Science ®Google Scholar
• Ornes S. (2013). Antibody-drug conjugates. Proc Natl Acad Sci USA 110:13695
   PubMed Web of Science ®Google Scholar
• Pro B, Avandi R, Brice P, et al. (2011). Durable remissions with brentuximab vedotin (SG-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL). J Clin Oncol 29:8032
   Google Scholar
• Remillard S, Rebhun LI, Howie GA, et al. (1975). Antimitotic activity of the potent tumor inhibitor maytansine. Science 189:1002–5
   PubMed Web of Science ®Google Scholar
• Sapra P, Betts A, Boni J. (2013). Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev Clin Pharmacol 6:541–54
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. (2012). Antibody therapy of cancer. Nat Rev Cancer 12:278–87
   PubMed Web of Science ®Google Scholar
• Shefet-Carasso L, Benhar I. (2014). Antibody-targeted drugs and drug resistance – challenges and solutions. Drug Resist Updat. doi: 10.1016/j.drup.2014.11.001
   Google Scholar
• Singh S. (2010). Naomedicine-nanoscale drugs and delivery systems. J Nanosci. Nanotechnol 10:7906–18
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–91
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, et al. (2002). The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 62:3736–42
   PubMed Web of Science ®Google Scholar
• Weiner LM, Surana R, Wang S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10:317–27
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. (2010). Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 363:1812–21
   PubMed Web of Science ®Google Scholar